{"nctId":"NCT01840605","briefTitle":"A Confirmatory Study of TAU-284 in Pediatric Patients With Atopic Dermatitis","startDateStruct":{"date":"2013-03"},"conditions":["Dermatitis","Atopic"],"count":303,"armGroups":[{"label":"TAU-284","type":"EXPERIMENTAL","interventionNames":["Drug: Bepotastine besilate"]},{"label":"ketotifen fumarate","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: ketotifen fumarate"]}],"interventions":[{"name":"Bepotastine besilate","otherNames":["TALION 5mg tablets"]},{"name":"ketotifen fumarate","otherNames":["ketotifen fumarate dry syrup"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients aged between 7 and 15 years\n* Patients giving assent and whose legal guardian giving informed consent\n* Outpatients\n* Patients diagnosed as atopic dermatitis\n* Patients who require the treatment with topical corticosteroid on areas other than face, head and neck\n* Patients whose diaries can be properly maintained\n* Patients who have 2 grades or more pruritus score\n\nExclusion Criteria:\n\n* Patients with bronchial asthma who require concomitant use of the corticosteroid\n* Patients who have been undergoing specific desensitization therapy or nonspecific immunomodulation therapy or phototherapy\n* Patients with current or previous history of drug hypersensitivity\n* Patients who have been treated with Bepotastine besilate in the past\n* Patients who have; a skin infection, or with zooparasite such as scabies and pediculosis; eczematous otitis externa with perforation in the eardrum; dermal ulcer, or profound heat burn or frostbite of the severity higher than the grade 2; on areas where topical corticosteroid is applied\n* Patients who have spastic disease such as epilepsy\n* Patients who concurrently have renal function abnormalities that may cause safety problems\n* Patients who do not give consent to use birth control\n* Pregnant patients, at risk of pregnancy or breastfeeding\n* Patients who had participated in any clinical trial in the last 12 weeks","healthyVolunteers":false,"sex":"ALL","minimumAge":"7 Years","maximumAge":"15 Years","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Pruritus Score","description":"The pruritus symptoms score were rated on 5-point scale ranging from 0 (none) to 4 (severe).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.669","spread":"0.058"},{"groupId":"OG001","value":"-0.638","spread":"0.058"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Pruritus Score","description":"The pruritus symptoms score were rated on 5-point scale ranging from 0 (none) to 4 (severe).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.425","spread":"0.047"},{"groupId":"OG001","value":"-0.510","spread":"0.047"}]}]}]},{"type":"SECONDARY","title":"Severity of Atopic Dermatitis at 2 Weeks (Change From Baseline)","description":"Severity score were rated on 5-point scale ranging from 0 (none) to 4 (severe).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"0.0"},{"groupId":"OG001","value":"-0.7","spread":"0.0"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Patient Impression Score (Reporting Excellent or Very Well Improved in Pruritus)","description":"Patient impression score were rated on 5-point scale ranging from 0 to 4 (4 excellent, 3 very well, 2 well, 1fair, 0 poor).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65.6","spread":null},{"groupId":"OG001","value":"65.1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":151},"commonTop":["Nasopharyngitis","Somnolence"]}}}